Current Report Filing (8-k)
10 6월 2022 - 6:07AM
Edgar (US Regulatory)
0001591165
false
0001591165
2022-06-03
2022-06-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 3,
2022
H-CYTE,
INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
001-36763 |
|
46-3312262 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2202
N. West Shore Blvd, Suite 200
Tampa,
FL |
|
33607 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(844)
633-6839
Copies
to:
Arthur
S. Marcus, Esq.
Sichenzia
Ross Ference LLP
1185
Avenue of the Americas
31st
Floor
New
York, New York
10036
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: Common Stock
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events
On
June 3, 2022, the Company closed its clinic in Scottsdale, Arizona. The Company has now closed all of its clinical operations in the
autologous infusion therapy business which delivered treatments for patients with chronic respiratory and pulmonary disorders. The Company
will continue to pursue regulatory approval of the device that was utilized in the treatment provided at the clinics. The
Company also has a continued interest in the commercialization of the denervex device. The Company has begun to transform itself into
a biologics and therapeutic device incubator to bring new technologies to market.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
H-CYTE,
INC. |
|
|
|
Date:
June 9, 2022 |
By: |
/s/
Jeremy Daniel |
|
|
Jeremy
Daniel |
|
|
Chief
Financial Officer |
H CYTE (QB) (USOTC:HCYT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
H CYTE (QB) (USOTC:HCYT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
H CYTE Inc (QB) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More H-cyte, Inc. News Articles